These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 9771846)

  • 1. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.
    Jordan SC; Quartel AW; Czer LS; Admon D; Chen G; Fishbein MC; Schwieger J; Steiner RW; Davis C; Tyan DB
    Transplantation; 1998 Sep; 66(6):800-5. PubMed ID: 9771846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I; Deutsch MA; Kauke T; Beiras-Fernandez A; Schmoeckel M; Vicol C; Sodian R; Reichart B; Spannagl M; Ueberfuhr P
    Exp Clin Transplant; 2008 Sep; 6(3):229-35. PubMed ID: 18954302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-HLA antibodies on the long-term survival of heart and kidney allografts.
    Barr ML; Cohen DJ; Benvenisty AI; Hardy M; Reemtsma K; Rose EA; Marboe CC; D'Agati V; Suciu-Foca N; Reed E
    Transplant Proc; 1993 Feb; 25(1 Pt 1):262-4. PubMed ID: 8438294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss.
    Panigrahi A; Gupta N; Siddiqui JA; Margoob A; Bhowmik D; Guleria S; Mehra NK
    Hum Immunol; 2007 May; 68(5):362-7. PubMed ID: 17462503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies.
    Akalin E; Dinavahi R; Friedlander R; Ames S; de Boccardo G; Sehgal V; Schröppel B; Bhaskaran M; Lerner S; Fotino M; Murphy B; Bromberg JS
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1160-7. PubMed ID: 18337549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.
    Matinlauri IH; Kyllönen LE; Eklund BH; Koskimies SA; Salmela KT
    Transplantation; 2004 Jul; 78(2):198-204. PubMed ID: 15280678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
    Wasowska BA; Qian Z; Cangello DL; Behrens E; Van Tran K; Layton J; Sanfilippo F; Baldwin WM
    Transplantation; 2001 Mar; 71(6):727-36. PubMed ID: 11330533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of antibodies in kidney transplant].
    Ruffoni E; Seveso M; Marson P; Tison T; Cozzi E
    G Ital Nefrol; 2012; 29 Suppl 54():S54-60. PubMed ID: 22388831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and Ig class of preformed alloantibodies causing a positive crossmatch in renal transplantation. The implications for graft survival.
    ten Hoor GM; Coopmans M; Allebes WA
    Transplantation; 1993 Aug; 56(2):298-304. PubMed ID: 7689256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
    Aubert V; Venetz JP; Pantaleo G; Pascual M
    Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients.
    Glotz D; Haymann JP; Sansonetti N; Francois A; Menoyo-Calonge V; Bariety J; Druet P
    Transplantation; 1993 Aug; 56(2):335-7. PubMed ID: 8356587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.
    Tyan DB; Li VA; Czer L; Trento A; Jordan SC
    Transplantation; 1994 Feb; 57(4):553-62. PubMed ID: 8116041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated rejection: treatment alternatives and outcomes.
    Singh N; Pirsch J; Samaniego M
    Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.